Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.
Topp MS, Duell J, Guijarro AMA, Odin M, Nielsen T, Rajeswaran A, Wenger M, Zundel C, Bogucka-Fedorczuk A, Wrobel T. Topp MS, et al. Haematologica. 2020 May;105(5):e256-e260. doi: 10.3324/haematol.2019.233189. Epub 2020 Feb 6. Haematologica. 2020. PMID: 32029506 Free PMC article. No abstract available.
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, Hensel F, Rosenwald A, Einsele H, Topp MS, Brändlein S. Rasche L, et al. Among authors: topp ms. Haematologica. 2015 Mar;100(3):377-84. doi: 10.3324/haematol.2014.117945. Epub 2015 Jan 30. Haematologica. 2015. PMID: 25637055 Free PMC article. Clinical Trial.
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.
Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M. Nagel I, et al. Among authors: topp ms. Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21. Blood. 2017. PMID: 28827408 Free PMC article. Clinical Trial.
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.
Duell J, Krummenast F, Schirbel A, Klassen P, Samnick S, Rauert-Wunderlich H, Rasche L, Buck AK, Wester HJ, Rosenwald A, Einsele H, Topp MS, Lapa C, Kircher M. Duell J, et al. Among authors: topp ms. J Nucl Med. 2021 Oct;62(10):1415-1421. doi: 10.2967/jnumed.120.257279. Epub 2021 Feb 12. J Nucl Med. 2021. PMID: 33579803 Free article.
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS, Eradat H, Florschütz A, Hochhaus A, Wrobel T, Walewski J, Knopinska-Posluszny W, Kanate AS, Lech-Maranda E, Brunnberg U, Chitra S, Nielsen TG, Sellam G, Shivhare M, Lossos IS. Topp MS, et al. J Cancer Res Clin Oncol. 2023 Feb;149(2):811-817. doi: 10.1007/s00432-021-03847-5. Epub 2022 Feb 18. J Cancer Res Clin Oncol. 2023. PMID: 35182224 Free PMC article.
150 results